Premium
Comments on pre‐fibrotic myelofibrosis and how should it be managed
Author(s) -
Barbui Tiziano,
Thiele Juergen,
Gisslinger Heinz,
Orazi Attilio,
Vannucchi Alessandro M.,
Gianelli Umberto,
BehamSchmid Christine,
Tefferi Ayalew
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15840
Subject(s) - myelofibrosis , medicine , grading (engineering) , bone marrow , clinical practice , ruxolitinib , context (archaeology) , myeloid , oncology , intensive care medicine , pathology , family medicine , paleontology , civil engineering , engineering , biology
Body, J.J., Bone, H.G., de Boer, R.H., Stopeck, A., Van Poznak, C., Damiao, R., Fizazi, K., Henry, D.H., Ibrahim, T., Lipton, A., Saad, F., Shore, N., Takano, T., Shaywitz, A.J., Wang, H., Bracco, O.L., Braun, A. & Kostenuik, P.J. (2015) Hypocalcaemia in patients with metastatic bone disease treated with denosumab. European Journal of Cancer, 51, 1812–1821. Fizazi, K., Lipton, A., Mariette, X., Body, J.J., Rahim, Y., Gralow, J.R., Gao, G., Wu, L., Sohn, W. & Jun, S. (2009) Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology, 27, 1564–1571. Ikesue, H., Tsuji, T., Hata, K., Watanabe, H., Mishima, K., Uchida, M., Egashira, N., Miyamoto, T., Baba, E., Akashi, K., Takayama, K., Nakanishi, Y., Tokunaga, E., Okamoto, T., Maehara, Y., Yokomizo, A., Naito, S., Kubo, M., Tanaka, M. & Masuda, S. (2014) Time course of calcium concentrations and risk factors for hypocalcemia in patients receiving denosumab for the treatment of bone metastases from cancer. Annals of Pharmacotherapy, 48, 1159–1165. Lai, F.P., Cole-Sinclair, M., Cheng, W.J., Quinn, J.M., Gillespie, M.T., Sentry, J.W. & Schneider, H.G. (2004) Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. British Journal of Haematology, 126, 192–201. Moreaux, J., Hose, D., Kassambara, A., Reme, T., Moine, P., Requirand, G., Goldschmidt, H. & Klein, B. (2011) Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration. Blood, 117, 1280–1290. Okada, N., Kawazoe, K., Teraoka, K., Kujime, T., Abe, M., Shinohara, Y. & Minakuchi, K. (2013) Identification of the risk factors associated with hypocalcemia induced by denosumab. Biological &/and Pharmaceutical Bulletin, 36, 1622–1626. Raje, N., Terpos, E., Willenbacher, W., Shimizu, K., Garcia-Sanz, R., Durie, B., Legiec, W., Krejci, M., Laribi, K., Zhu, L., Cheng, P., Warner, D. & Roodman, G.D. (2018) Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. The Lancet. Oncology, 19, 370–381. Terpos, E., Szydlo, R., Apperley, J.F., Hatjiharissi, E., Politou, M., Meletis, J., Viniou, N., Yataganas, X., Goldman, J.M. & Rahemtulla, A. (2003) Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood, 102, 1064–1069. Vij, R., Horvath, N., Spencer, A., Taylor, K., Vadhan-Raj, S., Vescio, R., Smith, J., Qian, Y., Yeh, H. & Jun, S. (2009) An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. American Journal of Hematology, 84, 650–656. Witteveen, J.E., van Thiel, S., Romijn, J.A. & Hamdy, N.A. (2013) Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature. European Journal of Endocrinology, 168, R45–R53.